Abstract 996P
Background
For unresectable hepatocellular carcinoma (uHCC), the efficacy of transarterial chemoembolization (TACE) monotherapy is not satisfactory. Some studies have shown that TACE combined with molecular targeted drugs and programmed death-1 (PD-1) inhibitors shows potential synergistic effects that can prolong the overall survival (OS) of patients with uHCC. Donafenib is a new generation of multi-kinase inhibitor which is approved as the first line treatment for uHCC. This study aimed to evaluate the efficacy and safety of TACE combined with donafenib plus PD-1 inhibitor (TACE+DP) and of TACE combined with donafenib (TACE+D) for uHCC in a multicenter retrospective study.
Methods
The clinical data of patients with uHCC who had received TACE+DP or TACE+D as first-line treatment from six Chinese academic centers, from July 2021 to July 2022, were collected and retrospectively analyzed. In the TACE+DP group, patients received intravenous administration of PD-1 inhibitor every three weeks and oral donafenib (0.2 g) twice daily until intolerable toxicity or disease progression. In the TACE+D group, patients received the same dose of donafenib 3-5 days after TACE. Overall survival (OS), progression-free survival (PFS), and tumor responses were evaluated between the two groups according to the modified RECIST criteria.
Results
A total of 157 patients in the TACE+D group and 166 patients in TACE+DP group were included in this study. Patients in the TACE+DP group had longer median OS (18.1 vs 13.2 months, P<0.001) and longer median PFS (10.6 vs 7.9 months, P<0.001) than those in the TACE+D group. Patients in the TACE+DP group achieved a higher ORR (50.6% vs 41.4%, P=0.019) and a higher disease control rate (DCR) (89.2% vs 82.8%, P=0.010) than those in the TACE+D group. There was no significant difference in the incidence and severity of adverse events in the TACE+DP and TACE+D groups (any grade, 92.9% vs. 94.6%, P=0.270; grade 3 or 4, 33.8% vs. 37.3%, P=0.253).
Conclusions
With favorable safety and tolerability, TACE combined donafenib with PD-1 inhibitors significantly improves PFS, OS, and ORR over TACE combined with donafenib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital of Zhengzhou University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18